Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Sun aims to strongarm Taro shareholders
India's Sun Pharmaceuticals just won't take no for an answer. After its merger deal with Israel's Taro Pharmaceuticals fell apart last month, Sun now says it's going to try to force the company's controlling shareholders to sell out. "We will do everything required to preserve our rights," Sun's chairman said in a statement. Both companies are suing over the collapsed deal. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
